Abstract
Deep brain stimulation (DBS) targeting the lateral habenula (LHb) is a promising therapy for treatment-resistant depression (TRD) but its clinical effect has been variable, which can be improved by adaptive DBS (aDBS) guided by a neural biomarker of depression symptoms. A clinically-viable neural biomarker is desired to classify depression symptom states, track both slow and fast symptom variations during the treatment, and respond to DBS parameter alterations, which is currently lacking. Here, we conducted a study on one TRD patient who achieved remission following a 41-week LHb DBS treatment, during which we assessed slow symptom variations using weekly clinical ratings and fast variations using daily self-reports. We recorded daily LHb local field potentials (LFP) concurrently with the reports during the entire treatment process. We then used machine learning methods to identify a personalized depression neural biomarker from spectral and temporal LFP features. The identified neural biomarker classified high and low depression symptom severity states with a cross-validated accuracy of 0.97. It further simultaneously tracked both weekly (slow) and daily (fast) depression symptom variation dynamics, achieving test data explained variance of 0.74 and 0.63, respectively. It finally responded to DBS frequency alterations. Our results hold promise to identify clinically-viable neural biomarkers to facilitate future aDBS for treating TRD.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05716555
Funding Statement
This work was supported in part by the National Natural Science Foundation of China under Grants 62336007 and 62306269, in part by the Zhejiang Provincial Natural Science Foundation of China under Grant LD24H090001, in part by the Key R&D Program of Zhejiang under Grant 2022C03011, in part by the Starry Night Science Fund of Zhejiang University Shanghai Institute for Advanced Study under Grant SN-ZJU-SIAS-002, in part by the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences under Grant 2023-PT310-01, and in part by the Fundamental Research Funds for the Central Universities under Grant 226-2024-00127.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received approval from the Ethics Committee of Zhejiang University School of Medicine Second Affiliated Hospital (protocol number 20210218)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The data supporting this study’s findings are available from the corresponding author upon reasonable request.